CONTENTS

1. Rheumatic Fever: Time for Newer Recommendations **1**
Ashutosh Marwah

❖ Burden of Rheumatic Fever and Rheumatic Heart Disease in India *1* ❖ Revised Jones Criteria for Acute Rheumatic Fever *1* ❖ Evidence of Preceding Streptococcal Infection *2* ❖ Problems in Diagnosis of Rheumatic Fever in Indian Scenario Using Jones Criteria *2* ❖ WHO Guidelines *2* ❖ Other Investigations to Aid Diagnosis of Rheumatic Fever *3* ❖ Do we Really Need New Guidelines? *3* ❖ Major Changes *3*

2. Pulmonary Hypertension: Evaluation and Optimizing Therapy in the Present Era **6**
Neeraj Awasthy

❖ Classification *6* ❖ Clinical Presentation *6* ❖ Basic Investigations *7* ❖ Baseline Assessment *12* ❖ Interventional Therapy *19* ❖ Transplantation *19*

3. Pulmonary Embolism: Anticoagulation/Lytics or Intervention for Whom? **23**
AK Khera, Rajeev Dhalwani

❖ Diagnostic Approach *23* ❖ Therapeutic Considerations *23* ❖ Management of Acute Pulmonary Embolism *23* ❖ Therapeutic Options: Indications, Contraindications, and Rationale for Use *25* ❖ Prognosis *31* ❖ Future Research *31*

4. Sleep Apnea and Cardiovascular Disease **33**
RS Chatterji, V Nangia, N Dalal, AK Singh

❖ Extent of the Problem *33* ❖ How Obstructive Sleep Apnea Affects Cardiovascular System? *33* ❖ Sympathetic and Parasympathetic Effects of Obstructive Sleep Apnea *34* ❖ Obstructive Sleep Apnea as an Inflammatory Condition *34* ❖ Hypercoagulability *34* ❖ Central Sleep Apnea and Cardiovascular System *34* ❖ Hypertension *35* ❖ Coronary Artery Disease *35* ❖ Heart Failure *35* ❖ Arrhythmias *36* ❖ Stroke *36* ❖ Pulmonary Hypertension *37* ❖ Cardiovascular Mortality *37*

5. Syncope: An Update **40**
TS Kler, Niti Chadha

❖ Impact on the Quality of Life of Patients with Syncope 40 ❖ Approach to Evaluation of a Patient of Syncope 40 ❖ Evaluation of a Patient of Syncope *41* ❖ Detailed Physical Examination and Electrocardiogram *41* ❖ Make a Provisional Diagnosis *41* ❖ Echocardiogram *41* ❖ Cardiac Rhythm Monitoring *41* ❖ Tilt-table Testing *42* ❖ Electrophysiology Study *42* ❖ Management of Patients with Vasovagal Syncope *43* ❖ Management Recommendations of Neurally Mediated Syncope (European Society of Cardiology/2009 Recommendations) *43*

6. Infective Endocarditis Update: What is the Difference Now? **45**
Vivek Kumar, Lal C Daga

❖ Etiology *45* ❖ Pathogenesis *45* ❖ Classification and Diagnosis *46* ❖ Clinical Presentation *48* ❖ Examination *48* ❖ Investigations *48* ❖ Treatment—Antimicrobial Therapy *48* ❖ Treatment Options for Streptococci (Penicillin Mic ≤0.125 Mg/L) *49* ❖ Treatment of Streptococci (Penicillin Mic >0.125 to ≤0.5Mg/L) *49* ❖ Treatment of Abiotrophia and *Granulicatella* Spp. *49* ❖ Treatment of Streptococci in Patients with Significant Penicillin Allergy (Penicillin Mic >0.5 Mg/L) *49* ❖ Recommendations for Enterococcal Endocarditis *50* ❖ Treatment Recommendations for Q Fever *51* ❖ Treatment Recommendations for Bartonella Infective Endocarditis *51* ❖ Other Gram-negative Bacteria *51* ❖ Fungal Endocarditis *51* ❖ Surgical Management *51*

7. Hypertension: Controversies in Newer Guidelines **56**
Ankush Sachdeva

❖ Understanding the Controversy *56* ❖ Basic Workup and Management of Hypertension *57* ❖ Trials Influencing the Guidelines *57* ❖ Understanding Joint National Committee (JNC) 8 Guidelines *59*

8. Statin-induced Myopathy **64**
Peeyush Jain

❖ Statin-induced Muscle Symptoms *64* ❖ Incidence *64* ❖ Mechanism of Statin Myopathy *65* ❖ Predisposing Factors *65* ❖ Determinants of Statin Myopathy *66* ❖ Low-density Lipoprotein Cholesterol Lowering in Statin Intolerant Patients *66* ❖ Management of Statin Myopathy *68* ❖ Persistence of Myopathy after Statin Withdrawal *68*

9. Atrial Fibrillation Update, 2014 **71**
Sanjiv Bharadwaj, Sujeet Narain

❖ Genetics Predisposition *71* ❖ Classification *71* ❖ Natural History *72* ❖ Clinical Presentation *72* ❖ Diagnosis *72* ❖ Management *72* ❖ Newer Antiarrhythmic Drug *76* ❖ Risk of Bleeding *78* ❖ Newer Antithrombotic Drugs *79* ❖ New Treatment Option *80* ❖ Newer Pharmacological Agents *81*

10. Newer Antiplatelets and Anticoagulants: Filling it into Clinical Practices **83**
Arvind Sethi, Upendra Kaul

❖ Antiplatelet Drugs *83* ❖ Antiplatelet Drug Resistance *83* ❖ Need for Newer Antiplatelet Drugs *84* ❖ Anticoagulants *86* ❖ New Oral Anticoagulants *87* ❖ Drug Interactions with New Oral Anticoagulants *92* ❖ Laboratory Testing and Monitoring for the NOAS *92* ❖ Perioperative Management *93* ❖ Complex Clinical Scenarios *93* ❖ Management of Bleeding Complications/Overdose *94* ❖ Choosing an Oral Anticoagulant *94*

11. Drug Management of Arrhythmias: Newer Insights **98**
Aseem Dhall, Satyendra Kumar Tiwari

❖ Newer Insights in Antiarrhythmic Treatment of Atrial Fibrillation *98*

12. Chest Radiography and Cardiovascular Disease: Is It Still Relevant in the Era of Other Imaging Modalities? **105**
Poonam Khurana, Rishabh Khurana

❖ Status of Chest Radiography: Past and Present *105* ❖ Status of Chest Radiography in Intensive Care Unit: A Unique and Indispensable Role *107* ❖ Role of Chest Radiography in Detection and Diagnosis of Congenital Heart Disease *108* ❖ Dependency of Other Modalities on Chest Radiography: Diagnosis of Cardiovascular Disease *108* ❖ Need and Importance of Repeat Imaging: Chest Radiography and Other Modalities *108* ❖ Radiologist, Clinicians, and Chest Radiography *109* ❖ Chest Radiography and Cardiovascular Disease: Summary and Conclusion *112*

13. Ambulatory Arrhythmia Monitoring Devices **115**
Niti Chadha

❖ Implantable Loop Recorders *115* ❖ Holter Monitor *115* ❖ Event Monitors *115* ❖ Who are the Candidates for Which Device? *120* ❖ Studies Comparing the Diagnostic Yields of Various Monitoring Devices *120*

14. Exercise Stress Testing (Stress Echocardiography): Where does it Stand with Other Modalities? **123**
Neel Bhatia, Sameer Shrivastava

❖ Overview *123* ❖ Indications of Stress Echocardiography *123* ❖ Advantages *124* ❖ Drawbacks of Exercise Stress Echocardiography *124* ❖ Pharmacologic Stress Testing *124* ❖ Appropriate Use Criteria 2011 *124* ❖ Exercise Echocardiography in Valvular Heart Disease *125* ❖ Diagnostic Accuracy *125* ❖ Conclusion *125* ❖ Future *127* ❖ Cardiac Computed Tomography *128* ❖ Cardiac CT Angiography *129* ❖ Future Directions in Noninvasive Testing *129*

15. Three-dimensional Echocardiography: Utility in Clinical Practice **132**
Vinay Kumar Sharma

❖ Data Acquisition Modes and Display of Images *132* ❖ Acquisition of the Three-dimensional Dataset *133* ❖ Clinical Applications of Three-dimensional Echocardiography *133*

16. Coronary CT Angiography Current Perspective: Redefining the Gold Standard for Coronary Angiography **142**
Mona Bhatia

❖ Lumenography *142* ❖ Insufficient Sampling *142* ❖ Quantitation of Minimum Luminal Area and Minimum Luminal Diameter *143* ❖ Overlap and Foreshortening *143* ❖ Plaque Composition, Distribution, and Severity *144* ❖ Technical Decision Making and Procedure Planning Using Coronary Computed Tomography Angiography *145* ❖ Clinical Decision Making *146* ❖ Additional Advantages of Coronary Computed Tomography Angiography *146* ❖ Evaluation of Myocardial Perfusion *147* ❖ Fractional Flow Reserve *147* ❖ Limitation of Coronary Computed Tomography Angiography *147* ❖ Advances in Coronary Computed Tomography Angiography Acquisitions *147*

17. Role of Nuclear Imaging for Damaged Ventricles **149**
Atul Verma, Sanjeev Pandey

❖ Myocardial Infarction *149* ❖ Role of Nuclear Imaging in Acute Coronary Syndrome *149*
❖ Acute ST-Segment Elevation Myocardial Infarction *150* ❖ Unstable Angina and Non–ST-Segment Elevation Myocardial Infarction *151* ❖ Non–ST-Segment Elevation Myocardial Infarction *152*
❖ Nuclear Imaging in Heart Failure *152* ❖ Cardiac Autonomic Imaging with Spect Tracers *153*
❖ Future Prospects of Nuclear Imaging in Heart Failure *154*

18. Blood Banking for Patient-care has Evolved **159**
RC Khurana

❖ Transfusion-related Acute Lung Injury *159* ❖ Transfusion-associated Cardiac Overload *159*
❖ Transfusion-related Immunomodulation *160* ❖ Post-transfusion Iron Overload *160*
❖ Transfusion-associated Graft Versus Host Disease *160* ❖ Avoiding Deleterious Effects of Transfusion *161*
❖ Universally Safe Blood *161* ❖ Novel Cellular Therapies *161*

19. Risk Markers for Atherothrombosis **163**
Dheeraj Gandotra, Subhash Chandra

❖ Conventional Risk Factors *163* ❖ Novel Atherosclerotic Risk Markers *165* ❖ Noninvasive, Imaging Markers/ Modalities to Evaluate Atherothrombosis *167* ❖ Direct Plaque Imaging *167*
❖ Intravascular Ultrasound *167* ❖ Molecular Imaging *168*

20. Cardiovascular Diseases in Women: Does the Gender Bias Exist? **172**
Malay Shukla, Aparna Jaswal

❖ What Next? *173*

21. What is Optimal Medical Therapy and What does it Achieve: Medical Management of Coronary Artery Disease—Is it a Full Circle Traveled? **175**
Amitesh Chakravarty, Vijay Kumar

❖ Stich: Surgical Treatment for Ischemic Heart Failure *175* ❖ Polypill for Increase in Treatment Compliance *176* ❖ Background *176* ❖ Global Scenario *176* ❖ Useful Therapies *176*
❖ Efficacy of Optimal Medical Therapy *177* ❖ Additional Therapies *177* ❖ Discussion *177*

22. Optimal Medical Therapy: What does it Mean and Deliver? **179**
Mitu A Minocha, Sachin V Chaudhary

❖ Management of Stable Coronary Artery Disease *179* ❖ Pharmacological Management of Stable Cad Patients *180* ❖ Anti-ischemic Drugs *180* ❖ Newer Agents *182* ❖ Drugs for Event Prevention *182*
❖ Optimal Medical Therapy or Myocardial Revascularization Therapy for Stable Angina: Recent Evidence *183*

23. Complications of Myocardial Infarction **188**
Nishant Kumar, Ashok K Omar, Anumeha Omar, Mitu A Minocha, Sameer Shrivatava
❖ Cardiogenic Shock *188* ❖ Arrhythmic Complication of Myocardial Infarction *189*

24. Heart Lung Machine for CABG: Should it be Relegated to Archives? **199**
Rajesh Chauhan, Sanjay Gupta
❖ The History of Coronary Artery Bypass Grafting *200* ❖ Discussion *207*

25. Coronary Artery Bypass Graft in Awake: A Reality Check **211**
KK Sharma, Devesh Dutta
❖ Advantages of Awake Coronary Artery Bypass *211* ❖ Disadvantages of Awake Coronary Artery Bypass *212* ❖ Current Status *212*

26. Surgery on Aorta: Current Status and Desires of a Surgeon **214**
Ajay Kaul
❖ History *214* ❖ Definition *214* ❖ Etiology *215* ❖ Indications for Surgery or Intervention *215* ❖ Operative Procedure *217* ❖ Operative Steps *218* ❖ Descending Thoracic and Thoracoabdominal Aneurysm *218* ❖ Paraparesis or Paraplegia *218*

27. Preoperative Anesthetic Considerations for Adult Cardiac Patient Undergoing Noncardiac Surgery **220**
Anil Karlekar
❖ The Challenge *220* ❖ Cardiac Clearance and Fitness for Surgery *221* ❖ Getting started: Unearthing the 'cardiac load' *222* ❖ Additional Tests *230* ❖ Optimization of Patient Status with medications and/or interventions *232*

28. Minimally Invasive Cardiac Surgery: Has it Delivered its Promise? **238**
Yugal K Mishra, Syed Asrar Ahmed Qadri
❖ Invasiveness of Conventional Cardiac Surgery *239* ❖ Minimally Invasive Coronary Artery Bypass Grafting *239* ❖ Minimally Invasive Direct Coronary Artery Bypass *239* ❖ Minimally Invasive Cardiac Surgery/Coronary Artery Bypass Grafting *240* ❖ Endoscopic Harvest of Conduits *240* ❖ Minimally Invasive Valve Surgery *241* ❖ Minimally Invasive Atrial Septal Defect Closure *243* ❖ Other Minimally Invasive Cardiac Procedures *243* ❖ Robotic Cardiac Surgery *243* ❖ Robot-assisted Coronary Artery Bypass Grafting *244* ❖ Robotic Internal Mammary Harvest *244* ❖ Robot-assisted Minimally Invasive Direct Coronary Artery Bypass *244* ❖ Open Chest Robotic Anastomosis *245* ❖ Totally Endoscopic Coronary Artery Bypass on Arrested Heart *245* ❖ Totally Endoscopic Coronary Artery Bypass on Beating Heart *245* ❖ Robotic Coronary Artery Bypass Grafting as Part of Hybrid Coronary Intervention *245* ❖ Robotic Atrial Septal Defect Surgery *245* ❖ Robotic Mitral Valve Surgery *246*

29. Management of Advanced Heart Failure **248**
Vishal Rastogi, Bhumika S Anand
❖ Surgically Implanted ❖ Ventricular Assist Device *248* ❖ Preprocedural Planning *248* ❖ Percutaneous Left Ventricular Assist Devices *249* ❖ Tandemheart *249* ❖ Impella *250* ❖ Extracorporeal Life Support *251*

30. Diastolic Heart Failure **253**
Sameer Srivastava, Avinash Verma
❖ Heart Failure *253* ❖ 40% or 50%—What should be the Cut-off? *254* ❖ Assessment of Diastolic Heart Failure *259* ❖ Management *263* ❖ Future *266*

31. Stem Cells: A New Horizon toward Cardiac Regenerative Medicine **270**
Vinay Sanghi, Khushboo Choudhury, Kenneth Lee Harris, Venkatesh Ponemone
❖ Sources of Progenitor Stem Cells *273* ❖ Routes of Progenitor Stem Cell Administration *274* ❖ Cell Migration and Homing *274* ❖ Human Clinical Trials *275* ❖ Mechanism of Action *277*

32. Left Main Stenting: Appropriate in Current Era **281**
Pramod Joshi, S Yadav, Dheeraj Gandotra, Suman Bhandari

❖ Importance of Left Main Coronary Artery Stenosis *281* ❖ Surgical Outcome in Left Main Disease *281* ❖ Results of Percutaneous Coronary Intervention with Bare-metal Stents in Left Main Stenosis *281* ❖ Evidence of Percutaneous Coronary Intervention with Drug-eluting Stent in Left Main Coronary Artery Stenosis *282* ❖ Who is the Good Candidate for LMCA Stenting? *286* ❖ Impact of Diabetes on the Clinical Outcome *286* ❖ Adjunctive Management *291* ❖ The Future *294*

33. Cardiomyopathies: Revisit Beyond 2013 **298**
Nishith Chandra, Nishant Kumar

❖ Hypertrophic Cardiomyopathy *298* ❖ Dilated Cardiomyopathy *300* ❖ Infiltrative Cardiomyopathy *301* ❖ Sarcoidosis *301* ❖ Fabry's Disease *302* ❖ Role of Genetic Test *303*

34. Cardiac Tumors: A Story of Unbridled Excitement! **307**
Biswajit Paul

❖ Case Vignette *307* ❖ When to Suspect Cardiac Tumors *308* ❖ Approach to Cardiac Tumors: The IFs and BUTs! *309* ❖ A Few Words on Imaging Modalities *309* ❖ Secondary Cardiac Tumors *309* ❖ Benign Primary Cardiac Tumors *310* ❖ Malignant Primary Cardiac Tumors *312*

35. Pregnancy and Heart Diseases: Advancement in Management **315**
Smita Mishra, Seema Thakur

Section I: Introduction, Epidemiology, Genetics, and Fetal Screening 315
❖ Epidemiology *315* ❖ Genetic Testing and Counseling *315*

Section II: General Consideration of Pregnancy with Cardiovascular Diseases 317
❖ Combating Stress on Cardiovascular System in Pregnancy and Parturition *317* ❖ Evaluation of Cardiac Reserve and Risk Scoring in Pregnancy with CVD *317* ❖ Cardiac Function in Pregnancy *318* ❖ Effect of Labor on Pregnancy with CVD *319* ❖ General Recommendations in Pregnancy with CVD *319* ❖ Modified WHO Classification of Maternal Cardiovascular Pregnancy Risk *320* ❖ Anesthesia in Pregnancy with CVD *321*

Section III: Cardiac Diseases in Pregnancy 327
❖ Pregnancy in Patients with Pre-existing Cardiomyopathies *327* ❖ Hypertension in Pregnancy *327* ❖ Valvular Heart Diseases *331* ❖ Congenital Heart Disease *334*

Section IV: Rhythm Disorder in Pregnancy 339
❖ Resting Electrocardiography *340* ❖ Direct Current Cardioversion *340* ❖ Implantable Cardioverter Defibrillators *340* ❖ Management of Specific Arrhythmias *340* ❖ Conclusion *342* ❖ Appendix *343* ❖ Drugs During Pregnancy and Breastfeeding *343* ❖ US Food and Drug Administration Classification *343*

36. Fluid and Electrolyte Management in Critically Ill Cardiac Patients **351**
Amit Varma, Rajat Agrawal, Pradyut Bag

❖ Fluid Resuscitation and Management *351* ❖ History of Fluid Resuscitation *351* ❖ Colloid Versus Crystalloid: Clinical Studies *351* ❖ Common Electrolyte Disorders *354* ❖ Principles of Potassium Replacement *357* ❖ Chronic Kidney Disease *359*

37. Transcatheter Aortic Valve Implantation: Status for Low Risk Group **363**
Vijay Kumar, Ashok Seth

❖ Risk Stratification in Transcatheter Aortic Valve Replacement *363* ❖ Studies on Transcatheter Aortic Valve Replacement for Low- and Intermediate-risk Patients *364*

38. Approach to Acyanotic Congenital Heart Diseases **367**
Neeraj Awasthy, S Radhakrishnan

❖ Classification of Acyanotic Congenital Heart Disease *367* ❖ Pathophysiology of Acyanotic Congenital Heart Disease *367* ❖ How to Suspect Acyanotic Congenital Heart Disease *369* ❖ Clinical Examination *370* ❖ Chest X-ray *373* ❖ Electrocardiogram *374* ❖ Echocardiography *377* ❖ Direction of Shunt and Pulmonary Arterial Pressure *383* ❖ Obstructive Lesions *383*

39. Approach to Congenital Cyanotic Heart Disease: Is It Entirely Surgical Approach? **389**
Rajat Gupta, Savitri Srivastava

❖ Duct-dependent Pulmonary Circulation *389* ❖ Duct-dependent Systemic Blood Flow *391* ❖ Patent Ductus Arteriosus-dependent Admixture Lesions *392* ❖ Pulmonary Hypertension of the Newborn *393* ❖ Cyanotic Patients *393* ❖ Pre- and Peroperative Catheter Interventions *394* ❖ Hybrid Procedures *394* ❖ Postoperative Cases *395*

40. Pediatric Cardiac Intensive Care: Expectations of the Future **397**
Parvathi U Iyer

❖ Indian Scenario and Difference *397* ❖ Challenges *398* ❖ Home Grown Strategies *398* ❖ Complex Arrhythmias *399* ❖ Newer Modalities in Treatment of Pulmonary Hypertension *399* ❖ Manpower and Workforce Issues *399*

41. Surgery for Congenital Heart Disease: In Search of Perfection! **400**
Krishna S Iyer

42. Role of Nurses in Cardiac Sciences **405**
Saramma Thomas

❖ Role of Informatics Nursing in Cardiac Sciences *405* ❖ Nursing in Cardiac Specialty Units (Heart Command Center/Coronary Care Units/Emergency Room) *405* ❖ Role of Cardiac Nurse in Preoperative Units *406* ❖ Role of Nurse in Cardiothoracic Operation Theater *406* ❖ Role of Nurse in Cardiopthoracic Recovery Units *407* ❖ High Dependency Units/Step Down Units Cardiac Nursing *407* ❖ Role of Cardiac Nurse in Cardiac Catheterization Laboratory *407* ❖ Patient and Family Education *407* ❖ Nurses Role in Cardiac Rehabilitation Unit *407* ❖ Cardiac Nurses as Mentors *407* ❖ Role of Cardiac Nurse in Knowledge and Skill Development *408* ❖ Role of Cardiac Nurse in Managing End of Life Issues *408*

43. Ethical and Legal Issues in Cardiology **409**
Vibhu Ranjan Gupta

❖ Consent *409* ❖ Consent Prerequisites *411* ❖ Timing of Consent *411* ❖ Special Consents *411* ❖ Validity Period of Consent *412* ❖ Ethical Concerns *412* ❖ Legal Concerns *412* ❖ Disclosure of Information *412* ❖ Ethical and Legal Issues in Emergency Cardiovascular Care *413* ❖ Society for Cardiovascular Angiography Code of Ethics *413* ❖ Legal Implications of Medical Records *414*

Index *417*